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1  | INTRODUC TION
Worldwide, increasing exposure to allergens and air pollution is con-
tributing to a marked increase in the incidence of chronic respira-
tory diseases, which are becoming a major public health challenge.1,2 
One of the main adverse features of these chronic diseases is bron-
chial hyperresponsiveness (BHR) to different exogenous constrictor 
stimuli, which precipitates exacerbation of lung function. Although 
many studies have attempted to clarify the pathophysiological 
mechanisms primarily involved in the occurrence of BHR,3 the spe-
cific pathways leading to chronic airway inflammation have not been 
fully elucidated.
New concepts have recently emerged that explain the impor-
tance of the autonomic nervous system in generating neurogenic 
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Summary
Although acute prophylactic administration of atropine modulates airway respon-
siveness, the role of the parasympathetic nervous system in the pathogenesis of sen-
sitization and in antigen- induced bronchoconstriction remains unclear. The aim of 
the present study is to determine whether blocking muscarinic receptors during 
chronic allergen exposure modulates lung responsiveness to the specific allergen. 
Forty rats were randomly assigned to one of the following five treatment groups: 
sensitization with saline vehicle, intraperitoneal injection of ovalbumin (1 mg) with or 
without atropine treatment (10 mg/kg per day) and repeated ovalbumin aerosol 
(1.25 mg/mL for 20 minutes) either alone or combined with atropine. Lung respon-
siveness to methacholine (4–16 μg/kg per minute) and intravenous ovalbumin (2 mg) 
was established before and 21 days after treatment with forced oscillations following 
bilateral vagotomy. Lung cellularity was determined by analysis of bronchoalveolar 
lavage fluid (BALF). A lung inflammatory response in all sensitized animals was de-
fined as an increase in the number of inflammatory cells in the BALF. Baseline res-
piratory mechanics and methacholine responsiveness on Days 0 and 21 were 
comparable in all groups. However, increases in airway resistance following intrave-
nous allergen challenge were significantly exacerbated in rats that received atropine. 
Inhibition of the cholinergic nervous system during allergic sensitization potentiates 
bronchoconstriction following exposure to the specific allergen. These findings high-
light the role of the cholinergic neuronal pathway in airway sensitization to a specific 
allergen.
K E Y W O R D S
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inflammation as a major contributor to airflow limitation. In the con-
cept of neurogenic inflammation, neural mediators are considered to 
contribute to the inflammatory microenvironment responsible for the 
airflow limitation that causes chronic pulmonary symptoms.4-7 Vagal 
afferent nerves in the lung play a significant role in modulating airway 
tone, with the bronchopulmonary sensory C- fibres being of particular 
importance.8-11 These C- fibres are very sensitive to various endoge-
nous inflammatory mediators and inhaled irritants.8-10 Both vagal con-
trol and afferent sensory C- fibres have been demonstrated to play key 
roles in antigen- induced bronchoconstriction in sensitized animals12-14; 
however, the involvement of the parasympathetic pathway during the 
sensitization period has not been characterized.
Thus, the aim of the present study was to characterize the general 
involvement of the cholinergic neural pathway in the development of 
BHR during allergen exposure. An earlier report suggesting that acute 
inhibition of the parasympathetic pathway before allergen challenge 
increased pulmonary inflation pressure15 led us to hypothesize that 
blockade of the parasympathetic pathway by blocking muscarinic 
receptors during allergen sensitization may modulate lung respon-
siveness to the specific allergen. In addition, to reveal the relative 
contributions of the central and peripheral lung to adverse allergen- 
induced changes in lung function, we assessed airway and tissue re-
sponses separately by using the forced oscillation technique (FOT).
2  | RESULTS
The present study was performed on 40 rats divided into five 
groups: a vehicle control group (C, n = 8), two groups receiving 
intraperitoneal injections of ovalbumin (OVA) with (S, n = 7) or with-
out atropine (O, n = 9) and a final two groups receiving repeated 
OVA aerosol either alone (OA, n = 7) or combined with atropine (SA, 
n = 9).
2.1 | End- expiratory lung volume
The results of end- expiratory lung volume (EELV) measurements 
normalized against bodyweight are shown in Figure 1. There were 
no differences in EELV between Days 0 and 21 within Groups C, O 
and S as evaluated by two- way repeated measures analysis of vari-
ance (ANOVA). However, in groups receiving atropine (Groups OA 
and SA), there was a significant increase in EELV on Day 21 com-
pared with Day 0 (P = 0.02 and P = 0.01, respectively).
2.2 | Methacholine challenge
Respiratory mechanical changes in response to methacholine 
(MCh) challenge on Days 0 and 21 in each group are shown in 
Figure 2. According to two- way repeated measures ANOVA, there 
was a significant interaction between group allocation and MCh 
responses in terms of airway resistance (Raw) and respiratory tis-
sue damping (G) on Day 21 (P < 0.002 and P < 0.001, respectively), 
indicating that these treatments affected lung responsiveness to 
MCh. Although MCh caused marked dose- dependent (4–16 μg/kg 
per minute) increases in Raw and G, the MCh- induced increases in 
respiratory tissue elastance (H) were mild but significant (P < 0.05). 
On Day 0, there were no significant differences between groups 
in Raw, G and H responses to all MCh concentrations tested. On 
F IGURE  1 End- expiratory lung volume normalized to bodyweight in the protocol groups measured before ( , Day 0) and after ( , Day 
21) the sensitization protocol with or without atropine treatment (left) and the relative changes between the two experimental days (right). 
Group C, control group with no treatment; Group O, a single intraperitoneal dose of ovalbumin sensitization; Group S, intraperitoneal 
ovalbumin with subsequent ovalbumin aerosol sensitization; Group OA, a single intraperitoneal dose of ovalbumin and continuous atropine 
during the sensitization period; Groups SA, intraperitoneal ovalbumin with subsequent ovalbumin aerosol sensitization and continuous 
atropine during the sensitization period. Horizontal continuous lines within the box mark the median values; the lower and upper boundaries 
of boxes indicate the 25th and 75th percentiles, respectively; the whiskers above and below the box indicate the 90th and 10th percentiles, 
respectively; dashed lines: mean values. *P < 0.05 between Days 0 and 21; #P < 0.05 vs zero
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Day 21, rats that did not receive atropine treatment (Groups C, 
O and S) had similar Raw, G and H responses to MCh as seen on 
Day 0. However, lung responsiveness to MCh was inhibited in rats 
that were treated continuously with atropine (Groups OA and SA; 
P < 0.05 for all). On Day 21, there was a tendency for an increased 
Raw response to MCh in Group OA compared with Day 0, but the 
difference did not reach statistical significance (P = 0.06). In con-
trast, in Group SA, the Raw response to MCh was increased on Day 
21 only for the highest concentration tested (16 μg/kg per minute; 
P = 0.02). Similar results were seen for G on Day 21 in atropine- 
treated rats, with the increased response to MCh only reaching 
statistical significance for the highest concentration tested (16 μg/
kg per minute). The MCh- induced changes in H were abolished in 
atropine- treated rats.
2.3 | Ovalbumin challenge
Temporal changes in respiratory mechanical parameters in re-
sponse to OVA are shown in Figure 3. Two- way repeated meas-
ures ANOVA revealed significant interactions between group 
allocation and OVA- induced Raw, G and H responses (P < 0.001, 
P < 0.001 and P < 0.05, respectively), indicating that the treat-
ments affected lung responsiveness to OVA. According to post 
hoc analyses, there were no significant changes in any parameters 
F IGURE  2 Changes in airway 
resistance (Raw) and in tissue damping 
(G) and elastance (H) in response to 
increasing iv doses of methacholine 
(MCh4- MCh16) assessed before (Day 0) 
and after sensitization (Day 21). *, #, $, 
§ and + denote statistically significant 
differences relative to the baseline (BL) in 
Groups ( ) C, ( ) O, ( ) S, ( ) OA  
and ( )SA, respectively. Symbol x 
denotes statistically significant difference 
relative to Group OA within a condition
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in response to OVA in Group C. Peak increases in the parameters 
evaluated following OVA challenge were seen approximately 
2–3 minutes after OVA injection in the sensitized rats. Moderate 
responses were observed in Group O and S rats, with mean (±SEM) 
peak percentage Raw responses in these groups of 62 ± 18% and 
63 ± 34%, respectively, compared with 11.9 ± 4.2% in Group C; 
these differences did not differ significantly because of consid-
erable interindividual variability (P = 0.12). However, marked 
and sustained OVA- induced increases in Raw were observed 
in both atropine- treated groups, with peak Raw changes of 
657 ± 245% and 177 ± 47% in Groups OA and SA, respectively 
(P < 0.05 vs Group C). Significant increases were seen in G and 
H 2, 3 and 4 minutes after OVA challenge in all OVA- treated 
groups (P < 0.05 for all), whereas corresponding increases in G 
and H were detected earlier and lasted longer in Groups S, OA 
and SA.
2.4 | Bronchoalveolar lavage
After the 3- week treatment period, the total number of cells in the 
bronchoalveolar lavage fluid (BALF) differed between groups: sensi-
tization with OVA aerosols (Groups S and SA) resulted in increased 
accumulation of inflammatory cells in the bronchoalveolar space 
(Figure 4a; P < 0.001, one- way ANOVA test on ranks). Regarding dif-
ferential cell counts in the BALF, significant neutrophil accumulation 
was observed at the expense of macrophages in OVA aerosol- treated 
rats (Groups S and SA; P < 0.05; Figure 4b). There was a tendency for 
an increase in the relative number of eosinophils in Groups S, OA and 
SA as compared to Group C, but the difference did not reach statisti-
cal significance (P = 0.078).
3  | DISCUSSION
The present study investigates the involvement of the choliner-
gic pathway during allergic airway sensitization. The results dem-
onstrate that inhibition of the parasympathetic nervous system 
during the sensitization period augments lung responsiveness to 
the specific allergen. These enhanced responses were manifested 
more markedly in mechanical changes, reflecting constriction 
of the main conducting airways, and, to a lesser extent, in me-
chanical indices characterizing respiratory tissue mechanics. This 
exacerbation was striking in rats systemically exposed to the al-
lergen, whereas repeated inhalation of the allergen after systemic 
sensitization blunted the intensified mechanical responses to the 
allergen. The excessive responses in respiratory mechanical pa-
rameters in rats with parasympathetic nerve blockade were as-
sociated with significant increases in the normalized static lung 
volume.
3.1 | Baseline measurements
There were no differences in basal airway or respiratory tissue 
mechanical parameters between the different groups. These 
findings are in agreement with previous reports of the lack of 
effect of OVA sensitization and atropine on baseline respiratory 
mechanics.16-18 However, in the present study there was an in-
crease in static lung volume in atropine- treated rats. This may be 
a consequence of the direct effect of atropine on EELV, which is 
in line with a previous report indicating that loss of parasympa-
thetic control in humans leads to increased functional residual 
capacity.19
F I GURE   3 Changes in airway resistance (Raw) and in tissue 
damping (G) and elastance (H) in response to the specific 
allergen (ovalbumin). *, #, $, § and + denote statistically 
significant differences relative to the baseline (BL) in Groups  
( ) C, ( ) O, ( ) S, ( ) OA and ( ) SA, respectively. α and 
x denote statistically significant difference relative to Groups C 
and OA, respectively, within a condition
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3.2 | Responses to a non- specific cholinergic agonist
The aim of the constrictor challenge with MCh was to evaluate how 
sensitization with OVA and prolonged atropine pretreatment af-
fect the lung response to a non- specific cholinergic agonist. In the 
present study, repeated OVA aerosol exposure generated chronic 
airway inflammation, manifested as the accumulation of neutrophils 
and a tendency for an increase in the number of eosinophils. These 
results are in agreement with previous studies in which similar sen-
sitization protocols were used.15,20 However, despite these cellular 
changes, there was no evidence of altered lung responsiveness to 
MCh. Following sensitization with aerosolized OVA, the coexist-
ence of bronchial inflammation and the lack of BHR to non- specific 
constrictor challenge are controversial, but our findings are in ac-
cordance with results indicating dissociated inflammatory and me-
chanical responses.15,21,22
Surprisingly, prolonged atropine treatment throughout the ex-
perimental period blunted, but did not abolish, the respiratory 
mechanical changes resulting from intravenous infusion of MCh. 
Detailed analyses of the responses in individual rats revealed that 
only two rats in Groups OA and SA responded to MCh in a simi-
lar way to rats that did not receive atropine, whereas all other rats 
(n = 5 each in Groups OA and SA) did not respond to MCh at all. 
These observations suggest that although the subcutaneously im-
planted pumps provided sufficient atropine to most rats to maintain 
general muscarinic receptor blockade, the pumps may have suffered 
a technical failure by the time of the second set of experiments in 
two rats from each of these group. However, the lack of weight gain 
in these outlier rats (data not shown) suggests that continuous at-
ropine administration led to a hypermetabolic state in these two 
rats. Nevertheless, the concentration of atropine in the circulation 
may not have been sufficient to block responses to MCh by Day 21, 
when the second set of experiments was performed. Therefore, we 
included these animals in data analyses, bearing in mind this poten-
tial drawback for the other findings.
3.3 | Responses to the specific allergen
In agreement with previous results,20,23 intravenous injection of 
the specific allergen in sensitized rats led to the development of 
bronchoconstriction via various mediators involved in immune and 
inflammatory responses. The lack of a difference in mechanical re-
sponses between Groups S and O may be attributed to the greater 
importance of topical administration of the allergen during the sen-
sitization period rather than its systemic delivery. This finding is in 
accordance with previous results demonstrating no differences in 
immune responses following local and systemic administration,24 
and revealing no need for a systemic adjuvant to induce airway 
inflammation.25
The main finding of the present study is the significant exacer-
bation of the anaphylactic lung constrictor response in rats treated 
with atropine throughout the sensitization period. This effect was 
somewhat diminished, but still significant, in rats that were exposed 
repeatedly to aerosolized OVA. This blunted response may be at-
tributed to the development of allergen tolerance in this group of 
rats as a consequence of a decrease in OVA- specific IgE antibod-
ies.26,27 Moreover, blocking vagal control of the lungs before aller-
gen challenge ensured that the magnitude of the response was not 
affected by the autonomic nervous system, but rather by local and 
systemic mediators.
The mechanisms potentially underlying these findings can be 
inferred from the results of previous studies. Atropine has similar 
affinities for muscarinic M2 and M3 receptors. The M3 receptors 
participate in constrictor responses of the airway smooth muscle, 
whereas prejunctional M2 receptors are part of a negative feedback 
loop by which the contractile response is inhibited.6 It is possible 
that the exaggeration of the allergen response is due to dominance 
of a diminished negative feedback loop following blockade of M2 
receptors rather than blockade of excitatory M3 receptors,
15 result-
ing in an imbalance in the constrictor- relaxation processes. Further, 
because muscarinic receptors are also expressed on eosinophils28 
and because there was a tendency for an increase in the number 
of eosinophils in the sensitized groups in the present study, block-
ing the receptors involved in the negative feedback loop may have 
further contributed to the increased activation. In addition, the en-
hanced allergen response could be attributed to amplification of the 
interaction between the airway nerves and eosinophils mediated by 
nerve growth factor.29 This concept is in line with previous results 
of an inhibited lung constrictor response following the selective 
blockade of M3 receptors.
30,31 Together, these observations clearly 
F IGURE  4  (A) Total and (B) differential 
cell counts in the bronchoalveolar lavage 
fluid in the protocol groups on Day 21. 
* and # denote statistically significant 
differences in the neutrophil and 
macrophage cell counts relative to those 
in Group C, respectively. ( ) Lymphocytes, 
( ) macrophages, ( ) neutrophils, ( ) 
eosinophils
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demonstrate the key role of the parasympathetic neural pathway in 
allergen sensitization.
3.4 | Limitations
A limitation inherent in the present study is related to differences in 
airway innervation between different species.32 This variability af-
fects the density and distribution of pre- and post- ganglionic nerve 
fibres, as well as the expression of nicotinic and muscarinic receptor 
subtypes. In addition to these anatomical differences, functional dis-
similarities can also be anticipated because rat bronchi synthesize 
and store substantially more of the main cholinergic neurotransmit-
ter acetylcholine than human airways.32 These factors warrant con-
sideration before extrapolating the findings of the present study to 
human lung diseases.
4  | CONCLUSIONS
The present study characterizes the potential role of the choliner-
gic parasympathetic nervous system in the modulation of lung re-
sponses to a specific allergen in an experimental model of airway 
sensitization. Although the potential benefit of anticholinergic 
therapy in already established asthma is not a matter of debate, 
concomitant blockade of muscarinic receptors during the period of 
sensitization resulted in enhanced lung responses to the specific al-
lergen. This observation highlights the importance of the cholinergic 
pathway in the sensitization process and the involvement of vagal 
control in allergen- induced bronchospasm.
5  | METHODS
5.1 | Sensitization and protocol groups
The experimental protocol was approved by the Experimental Ethics 
Committee of the University of Geneva and the Animal Welfare 
Committee of the Canton of Geneva, Switzerland. Brown Norway rats 
(Janvier SAS, Le Genest-Saint-Isle, France), 13 weeks old, were used in 
the experiments. The animals were housed in a chamber with artificial 
light for 12 hours/day. Food and water were available ad libitum.
The rats were randomly assigned to one of five protocol groups 
(Figure 5). Sensitizations and treatments were started with an in-
traperitoneal injection of either 1 mL of normal saline in the naive 
rats (Group C), or ovalbumin (OVA, 1 mg; Sigma- Aldrich, Buchs, 
Switzerland). OVA was injected with aluminium hydroxide (50 mg; 
Sigma- Aldrich) as an adjuvant in the rats receiving a single dose of 
OVA with (Group OA) and without (Group O) atropine treatments, as 
well as in rats sensitized with repeated aerosols with (Group SA) or 
without atropine (Group S). Twenty- minute aerosol exposures were 
daily applied for 5 days between Days 14 and 20 either with normal 
saline in the control group of rats (Group C) and in Groups O and OA, 
or with OVA (25 mg in 20 mL normal saline) in the sensitized animals 
in Groups S and SA.
Animals were placed two at a time in an exposure chamber con-
nected to a nebulizer (Syst’AM, Villeneuve- sur- Lot, France; type LS 
2000- 3011). In the animals in the two protocol groups in which the 
parasympathetic system was inhibited (Groups OA and SA), the ac-
tion of a subcutaneous pump (Alzet, Durect Corporation, Cupertino, 
CA, USA; 2 mL) that continuously administered atropine (10 mg/kg 
per day)33,34 diluted in ethanol and saline was initiated on Day 0. 
Under general anaesthesia, the pump was introduced under the dor-
sal skin into the back side of the animal, below the thoracic region.
5.2 | Anaesthesia and surgical preparations
On Day 0, the rats were anaesthetized with an intraperitoneal in-
jection of chloral hydrate (5%, 400 mg/kg; Sigma- Aldrich) to allow 
spontaneous breathing during measurement of EELV.35 To measure 
respiratory mechanics with the FOT (see below), the rats were then 
intubated (Portex ED 2.4 mm, ID 1.7 mm connected to Abbocath- T 
14G) and mechanically ventilated (a tidal volume of 7 mL/kg, a res-
piratory rate of 70 breaths/minute and a positive end- expiratory 
pressure (PEEP) of 2.5 cmH2O; Harvard Apparatus Inc. Holliston, 
MA, USA; Model 683 Rodent Ventilator). To minimize surgical inter-
vention, the rats were equipped with a superficial iv line in the femo-
ral area with a catheter (Vasculon 26G, BD Allschwil, Switzerland), 
and anaesthesia was maintained with an iv infusion of midazolam- 
fentanyl (both from Sintetica SA, Mendrisio, Switzerland) and atra-
curium (Labatec- Pharma, Geneva, Switzerland). On Day 21, the same 
anaesthetic protocol was performed with an additional catheterization 
F IGURE  5 Summary of the protocol 
groups and treatments in the sensitization 
period. NaCl, normal saline vehicle; OVA, 
ovalbumin; IP, intraperitoneal. Arrows 
indicate timing of interventions in the 
different groups
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of the femoral vein for administration of the anaesthetic drugs and 
cannulation of the femoral artery to register the systemic blood pres-
sure during the experiment (Abbocath- T 22G Abbott Medical, Zurich, 
Switzerland; acquisition data BIOPAC System MP100 ACE, Goleta, 
CA, USA). During both anaesthetic procedures, the animals were 
monitored with an electrocardiograph, allowing adaptation to the 
depth of anaesthesia. Body temperature was monitored with a rectal 
thermometer, and a heating pad (Harvard Apparatus Homeothermic 
Monitor for small animals, Holliston, MA, USA) was applied to maintain 
the temperature in the normal range (37 ± 0.5°C).
5.3 | Experimental protocol
The experimental protocol was designed to study EELV and MCh 
(Bichsel, Interlaken, Switzerland) responsiveness in a follow- up man-
ner, while the OVA provocations were limited to the second set of 
experiments.
The rats were anaesthetized and ventilated on Day 0, and EELV 
and baseline forced oscillatory respiratory mechanical measure-
ments were performed. MCh provocations were then induced 
with increasing doses of iv MCh (4, 8 and 16 μg/kg per minute). 
After a stabilization period allowing a steady- state response to 
develop (8–13 minutes), the changes in respiratory mechanics 
were assessed at 1- minute intervals by collecting at least three 
reproducible forced oscillatory recordings. After the highest dose 
of MCh, a 15- minute period was allowed for the animals to re-
cover; this ensured that there was no residual effect of MCh. The 
sensitization and treatment protocol was then performed on each 
animal.
On Day 21, the same experimental procedure was repeated 
by re- establishing the baseline EELV and respiratory mechanics, 
together with a repeated assessment of the MCh responsiveness. 
Bilateral vagotomy was then performed in the mid- cervical region. 
A second provocation challenge with the specific allergen OVA was 
then performed (2 mg iv).36 Three forced oscillatory recordings were 
collected at baseline, and individual oscillatory impedance data were 
then measured at 30- second intervals after the injection of the al-
lergen for 7 minutes or until a systemic hemodynamic collapse (mean 
systemic blood pressure reaching ~30 mm Hg). Finally, BALF was 
collected for the assessment of bronchial inflammation.
5.4 | Measurements
5.4.1 | End- expiratory lung volume
To assess EELV, the rats were placed in a supine position in a 
sealed Plexiglas chamber (2.8 L) and were ventilated at a PEEP of 
2.5 cmH2O, as detailed previously.
37 The mechanical ventilation 
was suspended before the registrations. At the time of suspen-
sion, the plethysmograph was opened to the atmosphere with the 
trachea opened to a pressurized chamber to equilibrate the lungs to 
a pressure of 2.5 cmH2O. The plethysmograph box was then closed 
and the pressures in the trachea (Ptr) and in the plethysmograph 
box (Pbox) were recorded simultaneously by miniature pressure 
transducers (Model 33NA002D; ICSensors, Milpitas, CA, USA) 
while the rats made spontaneous breathing efforts. Recordings 
included 6–8 breathing manoeuvres in a 10- second measurement 
period. Corrections for the thermal properties of the plethysmo-
graph were made in the recordings of Pbox. The corresponding 
changes in Ptr and Pbox were used to calculate EELV on the basis of 
Boyle’s law.37 For an exact comparison, the EELV data obtained on 
Days 0 and 21 were normalized to the bodyweights of the animals.
5.4.2 | Respiratory mechanics
Forced oscillation technique was applied to assess the contributions 
of the airway and tissue mechanical properties to the total respira-
tory resistance, as detailed previously.38,39 Briefly, the mechanical 
impedance of the respiratory system (Zrs) was measured during short 
apnoeic periods while the tracheal cannula was connected from the 
respirator to a loudspeaker- in- box system at end- expiration. A pseu-
dorandom forced oscillatory pressure signal was delivered by the loud-
speaker (frequency range 0.5–21 Hz) via a wave- tube (2 mm internal 
diameter, length 102 cm). Two identical pressure transducers (Model 
33NA002D; ICSensors, Milpitas, CA, USA) were used to measure the 
lateral pressures at the loudspeaker and at the tracheal end of the 
wave- tube, and Zrs was calculated from a fast Fourier transforma-
tion of the pressure- transfer function as the load impedance of the 
wave- tube.38
To assess the changes in the airway and tissue mechanical prop-
erties separately, a mathematical model containing a frequency- 
independent airway resistance (Raw) and inertance (Iaw) connected 
to a constant- phase tissue compartment,40 including damping (G) 
and elastance (H), was fitted to the Zrs spectra by minimizing the 
differences between the measured and modelled impedance values: 
where j is the imaginary unit, ω is the angular frequency (2πf), and 
α = 2/π arctan(H/G). It has been established that the Raw parame-
ter is primarily related to the overall airway geometry, as the contri-
bution of the chest wall to the frequency- independent Newtonian 
resistance is minor.41 The parameters G and H reflect the energy 
losses (damping or resistance) and the energy storage (stiffness or 
elastance) of the total respiratory system, respectively.41
5.4.3 | Bronchoalveolar lavage fluid
To evaluate the inflammatory lung response, we analysed the BALF. 
At the end of the second experiment, the trachea of the rat was con-
nected to a tube (Original Perfusor- Leitung PE, Braun 50 cm, Discofix 
35C) attached to a container (Syringe Omnifix 10 mL; Sigma- Aldrich, 
Buchs, Switzerland) filled with phosphate- buffered saline (PBS) posi-
tioned at a height of 20 cm, and filling was subsequently performed. 
When the hydrostatic filling reached a volume of 10 mL, the BALF 
was retained. The total number of cells in the BALF was counted by 
using a Neubauer chamber.
Zrs=Raw+ jωIaw+ (G− jH)∕ωα,
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The BALF was centrifuged in a 2 mL Eppendorf tube (750 rpm 
for 7 minutes). The supernatant was removed, and the pellet was re- 
suspended in an adequate quantity of PBS42 to obtain a concentra-
tion of 104 cells/100 μL. For cytological evaluation, a cytospin was 
performed with 100 μL of the suspended cells. The slides were fixed 
and stained with May- Grünwald- Giemsa solution (Sigma- Aldrich). 
Slices were scanned with a Mirax system (3DHistech, Budapest, 
Hungary). A collaborator who was uninformed of the experimental 
protocol manually counted a selected area inside the spot (with a 
Panoramic Viewer; 3DHistech) and discriminated the following cell 
types: eosinophil, macrophage, polymorphonuclear and lympho-
cyte. The total number of cells in the spot area was obtained by mul-
tiplying these counts by the total surface area.
5.5 | Statistical analyses
Data are presented as means ± SEM. The Shapiro- Wilk test was used 
to test data for normality, data were normalized by using a logarithmic 
transformation if normality test failed. Two- way repeated measures 
ANOVA tests, with time (Day 0 and Day 21) as the within group and the 
group allocation (C, O, S, OA and SA) as the independent factor, were 
performed to evaluate the differences in bodyweight and EELV be-
tween the protocol groups and to assess the effects of OVA on the res-
piratory mechanical parameters. Two- way repeated measures ANOVA 
tests, with within group variables of MCh dose (baseline, 4, 8 and 16 μg/
kg per minute) and between group factor of protocol groups (C, O, S, 
OA and SA), were used to evaluate the effects of treatments on lung re-
sponsiveness to the bronchoconstrictor provocation. Holm- Sidak tests 
were used for post hoc analyses. Data obtained from the BALF were 
not normally distributed, these data were analysed by using one- way 
ANOVA on ranks. P < 0.05 was considered statistically significant.
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